Key result
NOACs match VKAs for efficacy and bleeding within 3 months of surgical bioprosthesis in AF.
Why the study?
It was uncertain whether NOACs are as safe and efficient as vitamin K antagonists for thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and AF within 3 months of surgery.
Are non-vitamin K antagonist oral anticoagulants (NOACs) as safe and efficient as vitamin K antagonists (VKAs) regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?
Systematic Review
Are non-vitamin K antagonist oral anticoagulants (NOACs) as safe and efficient as vitamin K antagonists (VKAs) regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?
Available evidence from RCTs and observational cohorts suggests NOACs are as safe and effective as VKAs within the first 3 months after surgical bioprosthesis implantation in patients with atrial fibrillation, though dedicated adequately powered trials for the early postoperative period are still needed.
Answers are grounded in this paper and cite their sources.
Supports NOAC use early after bioprosthesis implantation in AF; confirms RCT non-inferiority yet leaves open need for dedicated powered trials.
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: 'Are NOACs as safe and efficient as vitamin K antagonist regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?' Altogether more than 324 papers were found using the reported search, of which 6 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The RIVER and ENAVLE trials showed non-inferiority of rivaroxaban (regarding mean time free from composite of death, major cardiovascular events or major bleeding at 12 months) and edoxaban (composite of death, clinical thromboembolic events or asymptomatic intracardiac thrombosis; and major bleeding) when compared with vitamin K antagonist. These studies include a low number of patients within 3 months of index surgery and overall low statistical power regarding this particular subgroup of patients. Data derived from lower evidence studies are compatible with the aforementioned findings. The available evidence suggests that non-vitamin K antagonist anticoagulants are as safe and as efficient as vitamin K antagonist regarding thromboembolic prophylaxis and bleeding event rates in patients with surgical bioprosthesis and atrial fibrillation within 3 months of bioprosthesis implantation. However, this evidence is derived from a limited number of studies with important methodological limitations. Expanding non-vitamin K antagonist anticoagulant recommendation to the early postoperative period warrants more confirmatory research.
No takes yet. Share an insight, caveat, or question.
Magro et al. (2021) conducted a systematic review in Surgical bioprosthesis and atrial fibrillation within 3 months of surgery. Non-vitamin K antagonist oral anticoagulants (NOACs: rivaroxaban, edoxaban, apixaban, dabigatran) vs. Vitamin K antagonists (VKA / warfarin) was evaluated on Thromboembolic prophylaxis efficacy and major bleeding safety. NOACs appear as safe and effective as VKAs for thromboembolic prophylaxis and major bleeding within 3 months of surgical bioprosthesis implantation in AF, with non-inferiority in RIVER and ENAVLE.
Synapse has enriched 10 related papers. Consider them for comparative context: